Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

If Opioid REMS Mandates Prescriber Training, Firms May Ask DEA For Help

Executive Summary

If FDA decides to incorporate mandatory prescriber training into a Risk Evaluation and Mitigation Strategy for extended-release opioids, industry implementation options include setting up an industry-wide registry or seeking congressional action to tie training verification into a Drug Enforcement Administration registry

You may also be interested in...



Purdue Seeks Equity In Abuse/Misuse Labeling For Immediate-Release Opioids

The manufacturer of extended-release oxycodone contends in a citizen petition that immediate-release and extended-release/long-acting opioid analgesics contain the same active ingredients and pose a similar risk of abuse, misuse and overdose.

FDA's CME Expectations For Opioid Prescribers Keep Sponsors At A Distance

Manufacturers of long-acting/extended-release opioids must develop a blueprint for physician education in pain management with their products, but otherwise will be involved only at arms’ length in the doctor training portion of the Risk Evaluation and Mitigation Strategies.

FDA's CME Expectations For Opioid Prescribers Keep Sponsors At A Distance

Manufacturers of long-acting/extended-release opioids must develop a blueprint for physician education in pain management with their products, but otherwise will be involved only at arms’ length in the doctor training portion of the Risk Evaluation and Mitigation Strategies.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052480

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel